<DOC>
	<DOCNO>NCT01339559</DOCNO>
	<brief_summary>This Phase 3 , open label , long term follow-up ( LTFU ) , multicenter , noncomparative , single arm study brivaracetam ( BRV ) .</brief_summary>
	<brief_title>Brivaracetam Safety Efficacy Follow-up Study Subjects With Epilepsy</brief_title>
	<detailed_description>The primary objective evaluate long term safety tolerability BRV individualized dos maximum 200 mg/day epilepsy subject .</detailed_description>
	<mesh_term>Epilepsy</mesh_term>
	<criteria>Subject complete Treatment Period N01358 evaluation period N01258 Male/female subject 16 year old . Subject 18 year may include legally permit ethically accept Subject Investigator believe reasonable benefit long term administration BRV may expect Female subject without childbearing potential ( premenarcheal , postmenopausal least 2 year , bilateral oophorectomy tubal ligation , complete hysterectomy ) eligible Subject develop hypersensitivity component investigational medicinal product ( IMP ) comparative drug state protocol course core study Severe medical , neurological , psychiatric disorder , laboratory value may impact safety subject Poor compliance visit schedule medication intake previous BRV study Planned participation clinical study another investigational drug device study Pregnant lactate woman Any medical condition , Investigator 's opinion , warrant exclusion Subject lifetime history suicide attempt suicidal ideation past 6 month</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Epilepsy</keyword>
	<keyword>Brivaracetam</keyword>
	<keyword>Partial Onset Seizures</keyword>
	<keyword>Adjunctive treatment</keyword>
</DOC>